ArticlePloS one2019

Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.

Antoine Chaillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.